Literature DB >> 11565613

Comparative studies on [Ca2+]i-level of fibroblasts from Alzheimer patients and control individuals.

A Palotás1, J Kálmán, G Laskay, A Juhász, Z Janka, B Penke.   

Abstract

The accumulation of the beta-amyloid peptide (betaAP) in the brain, produced from the ubiquitously expressed amyloid precursor protein (APP) is a defining feature of Alzheimer's disease (AD). Consistent with studies demonstrating the importance of skin biopsy in the diagnosis of neurodegenerative disorders, we investigated whether differences in intracellular free calcium levels ([Ca2+]i) of cultured cutaneous fibroblasts derived from sporadic AD patients and from age-matched control individuals might be present. [Ca2+]i was measured in Fura-2AM-loaded human fibroblasts by dual wavelength spectrofluorimetry. AD cells exhibited lower [Ca2+]i as compared to the control cultures. Exposure of fibroblasts to betaAP resulted in increased [Ca2+]i of the control cells, but not of AD fibroblasts. Our test could prove useful in supporting the diagnosis of (sporadic) AD in patients suspected of suffering from the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11565613     DOI: 10.1023/a:1011664102849

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  23 in total

1.  Lymphocytes as cell model to study apoptosis in Alzheimer's disease: vulnerability to programmed cell death appears to be altered.

Authors:  A Eckert; C W Cotman; R Zerfass; M Hennerici; W E Müller
Journal:  J Neural Transm Suppl       Date:  1998

Review 2.  [Diagnosis of neurometabolic and neurodegenerative diseases by cutaneous biopsy].

Authors:  M A Idoate Gastearena; F Vega Vázquez
Journal:  Rev Neurol       Date:  1997-09       Impact factor: 0.870

3.  Platelet activation in Alzheimer disease.

Authors:  S Sevush; W Jy; L L Horstman; W W Mao; L Kolodny; Y S Ahn
Journal:  Arch Neurol       Date:  1998-04

4.  Calcium mobilization evoked by amyloid beta-protein involves inositol 1,4,5-triphosphate production in human platelets.

Authors:  H Ishikawa; H Ozawa; T Saito; N Takahata; H Takemura
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

Review 5.  Translating cell biology into therapeutic advances in Alzheimer's disease.

Authors:  D J Selkoe
Journal:  Nature       Date:  1999-06-24       Impact factor: 49.962

6.  Altered calcium uptake in cultured skin fibroblasts from patients with Alzheimer's disease.

Authors:  C Peterson; G E Gibson; J P Blass
Journal:  N Engl J Med       Date:  1985-04-18       Impact factor: 91.245

7.  Deficient repair of DNA lesions in Alzheimer's disease fibroblasts.

Authors:  J C Li; E Kaminskas
Journal:  Biochem Biophys Res Commun       Date:  1985-06-28       Impact factor: 3.575

Review 8.  Calcium alterations in Alzheimer's disease: pathophysiology, models and therapeutic opportunities.

Authors:  A Pascale; R Etcheberrigaray
Journal:  Pharmacol Res       Date:  1999-02       Impact factor: 7.658

Review 9.  Fibroblast models of neurological disorders: fluorescence measurement studies.

Authors:  G P Connolly
Journal:  Trends Pharmacol Sci       Date:  1998-05       Impact factor: 14.819

10.  Amyloid beta-peptide(25-35) changes [Ca2+] in hippocampal neurons.

Authors:  H S Mogensen; D M Beatty; S J Morris; O S Jorgensen
Journal:  Neuroreport       Date:  1998-05-11       Impact factor: 1.837

View more
  2 in total

1.  The effect of citalopram on gene expression profile of Alzheimer lymphocytes.

Authors:  András Palotás; László G Puskás; Klára Kitajka; Miklós Palotás; József Molnár; Magdolna Pákáski; Zoltán Janka; Botond Penke; János Kálmán
Journal:  Neurochem Res       Date:  2004-08       Impact factor: 3.996

2.  Whole blood samples from Alzheimer patients and control donors demonstrate fluorimetric differences.

Authors:  András Palotás; János Kálmán; Miklós Palotás; Keyvan Matin; Károly Szentpáli; Attila Paszt; Zoltán Janka; Botond Penke
Journal:  Neurochem Res       Date:  2002-12       Impact factor: 3.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.